Ole Henrik André Brekke

Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway.

Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark.

Birkeland Innovasjon AS (Birkeland) is the technology transfer subsidiary of Inven2 AS in Norway. Established in 2004 as the technology transfer office of the University of Oslo, Norway's largest research institution, Birkeland manages the University's rights to research results that are suitable for commercialization. The firm is located in Oslo and is named for former physics professor Kristian Birkeland, founder of Norsk Hydro (OS: NHY), an international group active in oil and gas, aluminium and the production of fertilizers for agriculture.

Bio-Medisinsk Innovasjon AS engages in the development of biotechnology, bio-medical and pharmaceutical businesses. The firm acts as an investor and incubator for start-ups. The company was founded in 2004 and is headquartered in Oslo, Norway.